00:00 Intro 03:21 Revolutionary CD3 G.L.O.V.E does its job live in the field 15:46 Body cam released of the fatal shooting of Otis French Jr. 30:32 Officer cleared by SA in fatal shooting of ...

CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody CT-95 is Context’s second T cell engaging bispecific antibody to enter the clinic ...

A phase 1 open-label trial is underway, evaluating the safety and efficacy of CT-95 in patients with mesothelin-expressing ...

CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. They guide the immune system to find and eliminate cancer cells by binding tumor targets and the CD3 protein on ...

A nasal spray, referred to as nasal anti-CD3, could be the first FDA-approved treatment for traumatic brain injury, or TBI, that can be easily administered with no serious side effects ...

In addition, the association of CD3 with the TCR–peptide–MHC complex transmits the activation signal to intracellular signalling molecules to initiate a signalling cascade in the T cell.

Notably, IFT20 clusters with TCRs at the immune synapse and associates with the ζ- and ɛ-chains of CD3 in response to TCR engagement. TCR–CD3 complex assembly is initiated in the endoplasmic ...

CD20 × CD3 bispecific antibodies bind to both CD20 on malignant B cells and CD3 on T cells, bringing them into close proximity, which triggers T cell-mediated killing of the targeted B cells.

Context Therapeutics (CNTX) announced that the first patient has been dosed in the Phase 1 clinical trial of CT-95, a mesothelin x CD3 T cell ...